Voclosporin is a novel calcineurin inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. It was approved by the U.S. Food and Drug Administration (FDA) for the treatment of lupus nephritis (LN) on January 22, 2021.

Schisandrin C is a phytochemical lignan isolated from Schizandra chinensis Baill and shows anticancer-effects in human leukemia U937 cells.

E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells.

CC-122, also known as avadomide, binds to CRBN and induces degradation of aiolos and ikaros that result in cell apoptosis. It is a antitumor and immunomodulatory agent used to treat DLBCL.

CC-220 is a modulator of cereblon that is potential to treat systemic lupus erythematosis and multiple myeloma.

Indisulam is a carbonic anhydrase inhbitor and a synthetic sulfonamide targeting the G1 phase of the cell cycle.

Tasisulam is an antitumor agent and an apoptosis inducer via the intrinsic pathway.

CC-92480 is a cereblon E3 ubiquitin ligase modulating drug (CELMoD). CC-92480 shows high affinity to cereblon, resulting in potent antimyeloma activity .

(R)-CR8 is a cyclin dependent kinase (cdk) inhibitor with IC50 of 0.036 - 0.07 and 0.09 - 0.8 μM for cdk2 and cdk1,respectively.

CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity.

dCeMM4 is a molecular glue degrader, inducing ubiquitination and degradation of cyclin K by prompting an interaction of CDK12:cyclin K with a CRL7B ligase complex.

dCeMM2 is a molecular glue degrader, inducing ubiquitination and degradation of cyclin K by prompting an interaction of CDK12:cyclin K with a CRL5B ligase complex.

BI-3802 is a highly potent BCL6 degrader, inhibiting the BTB domain of BCL6, with an IC50 of ≤3 nM; BI-3802 has antitumor activity.